Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer’s disease

Resultado final

Letters and project updates to patient organisation Alzheimer Europe

AD patient organizations will be contacted to disseminate the project progress regarding AD diagnosis with the ADDIA assay to AD patients and their families, via announcements on patient organization’s websites and sending out letters.

Scientific papers prepared for peer-reviewed open access journals

Amoneta aims to raise the awareness, acceptance and support of the scientific and medical experts regarding the novel IVD assay for AD diagnosis:  Outcomes from the ADDIA project will be presented at international and national conferences.  Regular updates (in the form of abstracts, presentations, posters) regarding the progress of the project and the preliminary results will be provided to all relevant scientific organisations at European and international level.  Scientific articles of the findings of the clinical trial will be published in (open access) peer reviewed scientific and medical journals.

Publicaciones

ADDIA Chronobiology Study and Proof-of-Performance Study to Validate Blood-Based Biomarkers for the Diagnostic of early Alzheimer’s Disease (AD)

Autores: F. Blanc, F. Giovanni, M. Marizzoni, C. Mutter, J.C. Bier, F. Sellal, J.F. Démonet, S. Boutillier, H. Firat, S. Moussaoui, R. David, A. Ivanoiu, E. Magnin, A. Gabelle, F. Pasquier, H. Gurvit, B. Dubois
Publicado en: 2019
Editor: Alzheimer's and Parkinson's diseases

Addia, a Multi- Center Clinical Study of Proof-of-Performance to Validate Blood-Based Biomarkers for the Diagnostic of Alzheimer’s Disease (AD): The Study Protocol.

Autores: Bruno Dubois, MD, PhD, Professor, Jean-Christophe Bier, MD, Frederic Blanc, MD, PhD, Renaud David, MD, PhD, Jean-François Démonet, MD, PhD, Hüseyin Firat, MD, PhD, Giovanni B Frisoni, Prof, PhD, MD, Audrey Gabelle, MD, PhD, Hakan I. Gurvit, MD, Adrian Ivanoiu, MD, PhD, Eloi Magnin, MD, PhD, Moira Marizzoni, PhD, Saliha Moussaoui, PhD, Florence Pasquier, MD PhD and François Sellal, MD
Publicado en: 2018
Editor: Alzheimer's Association International Conference

Derechos de propiedad intelectual

NON-CODING RNAS (NCRNA) FOR THE DIAGNOSIS OF COGNITIVE DISORDERS

Número de solicitud/publicación: WO 2019048500
Fecha: 2017-09-05
Solicitante(s): AMONETA DIAGNOSTICS

DIPYRROMETHENE-BORON HYDROPHILIC FLUORESCENT COMPOUNDS

Número de solicitud/publicación: EP 09805741
Fecha: 2009-12-18
Solicitante(s): AMONETA DIAGNOSTICS

Unsaturated dibenzopyrromethene-boron borocarbons

Número de solicitud/publicación: WO2006/087458 2006/087458
Fecha: 2005-02-15
Solicitante(s): AMONETA DIAGNOSTICS

DIPYRROMETHENE-BORON HYDROPHILIC FLUORESCENT COMPOUNDS

Número de solicitud/publicación: EP 09805741
Fecha: 2009-12-18
Solicitante(s): AMONETA DIAGNOSTICS

Biological complex specific for Alzheimer's disease detection in vitro and use thereof

Número de solicitud/publicación: US20130289140 20130289140
Fecha: 2013-04-30
Solicitante(s): AMONETA DIAGNOSTICS

DETECTION OF NEURODEGENERATIVE DISEASES

Número de solicitud/publicación: EP 17719325
Fecha: 2017-03-07
Solicitante(s): AMONETA DIAGNOSTICS

NOVEL FLUORESCENT BORON-SUBSTITUTED DIPYRROMETHENES AND USE THEREOF FOR DIAGNOSIS

Número de solicitud/publicación: EP 09806180
Fecha: 2009-12-28
Solicitante(s): AMONETA DIAGNOSTICS